LGI3 Inhibitors

Leucine-rich Repeat LGI Family Member 3 (LGI3) inhibitors, as presented here, focus on indirectly modulating LGI3's function by targeting neuronal signaling and exocytosis pathways. Given LGI3's role in neuronal exocytosis, these inhibitors are selected to influence the broader context of neuronal signaling and vesicle trafficking. Neurotoxins like Botulinum toxin and Tetanus toxin are known for their potent inhibitory effects on neuronal exocytosis. By affecting neurotransmitter release, these toxins could indirectly impact LGI3's role in this process. Bafilomycin A1, by inhibiting vacuolar H+-ATPase, affects vesicle trafficking, a key component in exocytosis where LGI3 might be involved. Dynamin Inhibitor I, Dynasore, a dynamin inhibitor, and Latrunculin A, Latrunculia magnifica, which disrupts actin polymerization, target essential aspects of vesicular trafficking and cytoskeletal dynamics, potentially influencing LGI3-mediated exocytosis.

Tetrodotoxin (From Fugu sp.) and Saxitoxin, as sodium channel blockers, along with Omega-agatoxin and Ziconotide, calcium channel blockers, are included for their potential to modulate neuronal activity and signaling pathways relevant to LGI3's function. Clostridial toxins, which include a variety of neurotoxins affecting neuronal signaling and exocytosis, could also have an indirect impact on LGI3's function. JZL184, an inhibitor of monoacylglycerol lipase, is selected for its role in modulating endocannabinoid signaling, which might intersect with neuronal exocytosis processes where LGI3 is active. In summary, the approach to targeting LGI3 involves using compounds that influence neuronal signaling, vesicle trafficking, and the process of exocytosis. These inhibitors, by modulating these aspects of neuronal function, offer a potential route to indirectly influence LGI3's activity, particularly in the context of its role in regulating neuronal exocytosis.